KDR and hepatocellular carcinoma: Apatinib, a new selective inhibitor of VEGFR2 tyrosine kinase and an anti-angiogenic medication, showed satisfactory efficiency in unresectable HCC or advanced liver carcinosarcoma (Liu et al., 2018; Zhao et al., 2019).